Literature DB >> 11440899

GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.

A Brandt1, M Katschinski, R Arnold, K S Polonsky, B Göke, M M Byrne.   

Abstract

The present study was undertaken to establish in normal volunteers the alterations in beta-cell responsiveness to glucose associated with a constant infusion of glucagon-like peptide-1 (GLP-1) or a pretreatment infusion for 60 min. A high-dose graded glucose infusion protocol was used to explore the dose-response relationship between glucose and insulin secretion. Studies were performed in 10 normal volunteers, and insulin secretion rates (ISR) were calculated by deconvolution of peripheral C-peptide levels by use of a two-compartmental model that utilized mean kinetic parameters. During the saline study, from 5 to 15 mM glucose, the relationship between glucose and ISR was linear. Constant GLP-1 infusion (0.4 pmol x kg(-1) x min(-1)) shifted the dose-response curve to the left, with an increase in the slope of this curve from 5 to 9 mM glucose from 71.0 +/- 12.4 pmol x min(-1) x mM(-1) during the saline study to 241.7 +/- 36.6 pmol x min(-1) x mM(-1) during the constant GLP-1 infusion (P < 0.0001). GLP-1 consistently stimulated a >200% increase in ISR at each 1 mM glucose interval, maintaining plasma glucose at <10 mM (P < 0.0007). Pretreatment with GLP-1 for 60 min resulted in no significant priming of the beta-cell response to glucose (P = 0.2). Insulin clearance rates were similar in all three studies at corresponding insulin levels. These studies demonstrate that physiological levels of GLP-1 stimulate glucose-induced insulin secretion in a linear manner, with a consistent increase in ISR at each 1 mM glucose interval, and that they have no independent effect on insulin clearance and no priming effect on subsequent insulin secretory response to glucose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11440899     DOI: 10.1152/ajpendo.2001.281.2.E242

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  12 in total

1.  Logistic model of glucose-regulated C-peptide secretion: hysteresis pathway disruption in impaired fasting glycemia.

Authors:  Daniel M Keenan; Rita Basu; Yan Liu; Ananda Basu; Gerlies Bock; Johannes D Veldhuis
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.

Authors:  Benedikt A Aulinger; Torsten P Vahl; Hilary E Wilson-Pérez; Ron L Prigeon; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2015-03-31       Impact factor: 5.958

3.  Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.

Authors:  Akifumi Kushiyama; Takako Kikuchi; Kentaro Tanaka; Tazu Tahara; Toshiko Takao; Yukiko Onishi; Yoko Yoshida; Shoji Kawazu; Yasuhiko Iwamoto
Journal:  World J Diabetes       Date:  2016-06-11

4.  Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test.

Authors:  Jonas B Møller; William J Jusko; Wei Gao; Torben Hansen; Oluf Pedersen; Jens J Holst; Rune V Overgaard; Henrik Madsen; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-09-16       Impact factor: 2.745

5.  Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.

Authors:  M F Crutchlow; M Yu; Y-S Bae; S Deng; D A Stoffers
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

6.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

Review 7.  Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.

Authors:  Simon A Hinke; Karine Hellemans; Frans C Schuit
Journal:  J Physiol       Date:  2004-06-04       Impact factor: 5.182

8.  Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.

Authors:  Matheni Sathananthan; Luca P Farrugia; John M Miles; Francesca Piccinini; Chiara Dalla Man; Alan R Zinsmeister; Claudio Cobelli; Robert A Rizza; Adrian Vella
Journal:  Diabetes       Date:  2013-04-01       Impact factor: 9.461

9.  Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Authors:  Dale S Edgerton; Kathryn M S Johnson; Doss W Neal; Melanie Scott; Charles H Hobbs; Xia Zhang; Alokesh Duttaroy; Alan D Cherrington
Journal:  Diabetes       Date:  2008-10-07       Impact factor: 9.461

10.  Limited recovery of β-cell function after gastric bypass despite clinical diabetes remission.

Authors:  Roxanne Dutia; Katrina Brakoniecki; Phoebe Bunker; Furcy Paultre; Peter Homel; André C Carpentier; James McGinty; Blandine Laferrère
Journal:  Diabetes       Date:  2013-12-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.